Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.
Arkansas Attorney General Dustin McDaniel said Thursday he plans to ask the state Supreme Court...
Johnson & Johnson has entered a multi-year agreement to be the Official Healthcare Partner...
Johnson & Johnson today announced that it has accepted the binding offer from The Carlyle...
Lawyers and advocates for women alleging Johnson & Johnson products injured them are urging the U.S. Justice Department to investigate their claims the health care giant deliberately destroyed many documents critical to the lawsuits.
The Arkansas Supreme Court on Thursday overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker's marketing of the antipsychotic drug Risperdal. The court ruled that the state improperly sued under a law that applies to health care facilities, not pharmaceutical companies.
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price.
The British consumer goods company Reckitt Benckiser is buying K-Y personal lubricants from U.S. health care giant Johnson & Johnson. Terms of the deal were not disclosed Monday by Reckitt Benckiser, which expects to close the acquisition by the middle of the year.
Subsidiaries of Johnson & Johnson have agreed to pay $5.9 million to settle a lawsuit with Montana over how an anti-psychotic drug was marketed, state Attorney General Tim Fox said Thursday. The settlement with Janssen Ortho LLC and Janssen Pharmaceuticals closes the latest in a string of...
The contractor working for New Jersey's largest utility at the site of a town house explosion that killed one resident recently had been fined more than $100,000 by safety regulators for problems at two other sites, but the utility said Wednesday it never had any problems with the construction...
A lawyer for two drug companies told the Arkansas Supreme Court that the state improperly relied on federal regulations in a lawsuit that resulted in a $1.2 billion award over the companies' marketing of an antipsychotics drug.
A federal judge has ruled in favor of a manufacturer in a lawsuit brought by a Texas woman who claimed her pelvic pain was caused by implanted surgical mesh. U.S. District Judge Joseph R. Goodwin on Tuesday dismissed Carolyn Lewis' lawsuit against Johnson & Johnson subsidiary Ethicon.
The Food and Drug Administration has rejected — for a third time — Johnson & Johnson's application to expand use of the blood thinner Xarelto to reduce dangerous blood clots and related problems in patients with coronary artery disease.
A dozen plaintiffs filed the lawsuit in Texas in 2012. It is among about 50,000 cases filed nationwide that were transferred to West Virginia as part of federal multidistrict litigation. U.S. District Judge Joseph R. Goodwin selected the lawsuit and several other "bellwether" cases to serve as representative cases.
Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.
A divided Louisiana Supreme Court has overturned a $330 million judgment against two pharmaceutical companies that state Attorney General James "Buddy" Caldwell accused of improperly marketing a drug.
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public Health (Janssen GPH), an important new group unifying Janssen's commitment to research, develop, and deliver transformational medicines to address the world's greatest unmet public health needs.
Johnson & Johnson today announced sales of $18.4 billion for the fourth quarter of 2013, an increase of 4.5% as compared to the fourth quarter of 2012.
A proposed transaction between Johnson & Johnson (JNJ) and The Carlyle Group is viewed as strategically sound, according to Fitch Ratings. Fitch believes the margins and long-term growth opportunities for this business had been lower versus those for the total firm.
A panel of Food and Drug Administration experts again rejected Johnson & Johnson's bid to expand use of its blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease. The condition occurs when narrowed blood vessels restrict blood flow to the heart, increasing the risk of heart attack and other potentially deadly problems.
The Carlyle Group has agreed to acquire Johnson & Johnson’s Ortho-Clinical Diagnostics (OCD) business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases, for $4.15 billion.
The Arkansas Supreme Court has scheduled oral arguments in Johnson & Johnson's request to overturn a verdict and $1.2 billion fine over the marketing of the antipsychotics drug Risperdal.
Shares of Johnson & Johnson moved higher Tuesday after an RBC Capital Markets analyst upgraded the stock, saying he expects strong sales of the company's newest drugs.
Johnson & Johnson is paying North Dakota $923,000 as part of a $1.2 billion national settlement over allegations it illegally promoted two of its best-selling antipsychotics drugs. The state Department of Human Services says North Dakota's share of proceeds comes from a settlement announced last month.
The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.
The Food and Drug Administration said Wednesday that it reached a $1.25 million settlement with a division of Johnson & Johnson over allegations that it knowingly shipped faulty sterilization equipment used by hospitals.
Federal regulators on Friday approved a new drug from Johnson & Johnson for use in treating chronic hepatitis C infections. The U.S. Food and Drug Administration said it approved the drug, a protease inhibitor that blocks a protein needed by the virus to replicate.
Johnson & Johnson said late Tuesday that it will pay $2.5 billion to settle thousands of lawsuits brought by hip replacement patients who accuse the company of selling faulty implants that led to injuries and additional surgeries.
Ohio's Medicaid program will receive $52.7 million through a national settlement with a pharmaceutical company. The $2.2 billion settlement announced Monday involves Johnson & Johnson, one of its subsidiaries, the federal government and several states.
- Page 1